Akebia Ther (AKBA)vsAstraZeneca PLC (AZN)
AKBA
Akebia Ther
$1.40
+1.45%
HEALTHCARE · Cap: $364.82M
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 24769% more annual revenue ($58.74B vs $236.20M). AZN leads profitability with a 17.4% profit margin vs -2.3%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AKBA
Avoid31
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AKBA.
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 23.9% year-over-year
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Areas to Watch
Trading at 11.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AKBA
The strongest argument for AKBA centers on Revenue Growth. Revenue growth of 23.9% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bear Case : AKBA
The primary concerns for AKBA are Price/Book, EPS Growth, Market Cap.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
AKBA profiles as a growth stock while AZN is a value play — different risk/reward profiles.
AKBA carries more volatility with a beta of 0.37 — expect wider price swings.
AKBA is growing revenue faster at 23.9% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 31/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akebia Ther
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?